A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
Latest Information Update: 23 Dec 2023
At a glance
- Drugs F 652 (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Sponsors Evive Biotech
- 29 Jan 2022 Status changed from recruiting to discontinued.
- 03 Nov 2021 Planned primary completion date changed from 30 Sep 2021 to 31 Dec 2021.
- 11 Dec 2020 Planned initiation date changed from 10 Aug 2020 to 1 Dec 2020.